In ovarian cancer cells, it has been demonstrated that fibroblast growth factor (FGF2) results in increased expression of SLUG and ZEB1 by activating the PI3K/AKT/mTOR and MAPK/ERK signaling pathways (Lau et al., 2013). This evidence concerns the gene FGF2 and ovarian carcinoma.